Literature DB >> 2989319

Excess mineralocorticoid receptor activity in patients with dexamethasone-suppressible hyperaldosteronism is under adrenocorticotropin control.

P W Speiser, K O Martin, G Kao-Lo, M I New.   

Abstract

Total mineralocorticoid activity in human serum was assessed by the rat renal slice receptor assay (RRA). RRA values were compared to RIA-derived aldosterone (aldo) equivalents. Our data demonstrate that in normal subjects, mineralocorticoid receptor-binding steroids can be almost totally accounted for by immunoreactive deoxycorticosterone, corticosterone, cortisol, and aldo (RRA, 4.73 +/- 1.34 ng/ml aldo; RIA, 3.91 +/- 1.52 ng/ml aldo equivalents), while in 8 patients with dexamethasone-suppressible hyperaldosteronism (DSH), RRA values were greater than RIA values in the basal state (RRA, 7.57 +/- 0.75; RIA, 3.24 +/- 0.34; P less than 0.01). DSH patients had a RRA to RIA ratio after ACTH stimulation similar to the ratio in these patients in the basal state (basal, 2.34; ACTH-stimulated, 2.04). During dexamethasone treatment, RRA values fell markedly (1.82 +/- 0.26). Thus, total mineralocorticoid activity, as measured by RRA in DSH patients, was greater than RIA-measurable deoxycorticosterone, corticosterone, cortisol, and aldo, indicating the presence of an unidentified steroid which is dexamethasone suppressible and ACTH stimulable.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989319     DOI: 10.1210/jcem-61-2-297

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

Review 1.  Low-renin hypertension of childhood.

Authors:  J DiMartino-Nardi; M I New
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

2.  Dexamethasone-suppressible hyperaldosteronism: pathophysiology, clinical aspects, and new insights into the pathogenesis.

Authors:  F Fallo; N Sonino; M Boscaro; D Armanini; F Mantero; H G Dörr; D Knorr; U Kuhnle
Journal:  Klin Wochenschr       Date:  1987-05-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.